With Yervoy-beating data, Opdivo poised to fight melanoma's return after surgery

[D.ap]

“MADRID, Spain—Bristol-Myers Squibb has been pitting its immunotherapies Opdivo and Yervoy against melanoma as a combination treatment. But that doesn’t mean it’s not still testing the newer Opdivo on its own in the disease—even against its partner.

In fact, in a head-to-head trial in patients with advanced melanoma who had undergone surgery to remove their tumors, Opdivo has so far done a better job preventing cancer’s return—and with less likelihood of severe side effects.”

Details of an interim analysis revealed at the European Society of Medical Oncology Congress Monday showed the difference. Opdivo cut the chance of a recurrence by more than a third compared with Yervoy, which is now the standard of care in that setting, the company said

https://www.fiercepharma.com/pharma/yer ... er-surgery